Abstract
Historically, through the conduct of prospective clinical trials, breast cancer surgeons have performed less radical breast and axillary surgeries with no survival decrement to our patients. Currently, other opportunities exist for the treating breast surgeon to do less. Possibilities include active surveillance for ductal carcinoma in situ, ablative therapy for small primary breast cancers, selective omission of a sentinel node biopsy, and selective elimination of breast surgery after neoadjuvant systemic therapy. Breast surgeons must be leaders in the development and testing of effective therapy with the least intervention possible.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-6 |
| Number of pages | 6 |
| Journal | Annals of Surgical Oncology |
| DOIs | |
| State | Accepted/In press - Jul 2 2018 |
Fingerprint
ASJC Scopus subject areas
- Surgery
- Oncology
Cite this
The Changing Paradigms for Breast Cancer Surgery : Performing Fewer and Less-Invasive Operations. / Ollila, David W.; Hwang, E. Shelley; Brenin, David R.; Kuerer, Henry M.; Yao, Katharine; Feldman, Sheldon M.
In: Annals of Surgical Oncology, 02.07.2018, p. 1-6.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The Changing Paradigms for Breast Cancer Surgery
T2 - Performing Fewer and Less-Invasive Operations
AU - Ollila, David W.
AU - Hwang, E. Shelley
AU - Brenin, David R.
AU - Kuerer, Henry M.
AU - Yao, Katharine
AU - Feldman, Sheldon M.
PY - 2018/7/2
Y1 - 2018/7/2
N2 - Historically, through the conduct of prospective clinical trials, breast cancer surgeons have performed less radical breast and axillary surgeries with no survival decrement to our patients. Currently, other opportunities exist for the treating breast surgeon to do less. Possibilities include active surveillance for ductal carcinoma in situ, ablative therapy for small primary breast cancers, selective omission of a sentinel node biopsy, and selective elimination of breast surgery after neoadjuvant systemic therapy. Breast surgeons must be leaders in the development and testing of effective therapy with the least intervention possible.
AB - Historically, through the conduct of prospective clinical trials, breast cancer surgeons have performed less radical breast and axillary surgeries with no survival decrement to our patients. Currently, other opportunities exist for the treating breast surgeon to do less. Possibilities include active surveillance for ductal carcinoma in situ, ablative therapy for small primary breast cancers, selective omission of a sentinel node biopsy, and selective elimination of breast surgery after neoadjuvant systemic therapy. Breast surgeons must be leaders in the development and testing of effective therapy with the least intervention possible.
UR - http://www.scopus.com/inward/record.url?scp=85049584209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049584209&partnerID=8YFLogxK
U2 - 10.1245/s10434-018-6618-z
DO - 10.1245/s10434-018-6618-z
M3 - Article
SP - 1
EP - 6
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
ER -